Real-world Clinical Outcomes in Non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) Patients in Australia

被引:0
|
作者
Gupta, Karan [1 ]
Goh, Jeffrey [1 ]
Gan, Chun [1 ]
Anton, Arsha [2 ,3 ]
Weickhard, Andrew
Azad, Arun
Uccellini, Anthony
Brown, Stephen
Wong, Shirley
Parente, Phillip [2 ]
Shapiro, Julia
Liow, Elizabeth
Torres, Javier [2 ,4 ]
Parnis, Francis [5 ]
Steer, Christopher [6 ]
Warren, Mark
Gibbs, Peter [3 ]
Tran, Ben [7 ]
机构
[1] ANZUP, Camperdown, NSW, Australia
[2] Monash Univ, Melbourne, Vic, Australia
[3] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[4] Univ Melbourne, Rural Med Sch, Melbourne, Vic, Australia
[5] Univ Adelaide, Adelaide, SA, Australia
[6] Univ NSW, Rural Clin Campus, Albury, NSW, Australia
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
abs67
引用
收藏
页码:93 / 94
页数:2
相关论文
共 50 条
  • [41] Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
    Patel, Jeetvan
    Nguyen, Jennifer
    Bollu, Vamsi
    Kang, Barinder
    Sawhney, Amrita
    Byrne, Clare
    Tang, Jackson
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.
    Attard, Gerhardt
    Saad, Fred
    Tombal, Bertrand F.
    Hussain, Maha
    Sternberg, Cora N.
    De Phung
    Naidoo, Shevani
    Modelska, Katharina
    Reisman, Arlene
    Ivanescu, Cristina
    Penson, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide
    Pollock, YaoYao
    Smith, Matthew R.
    Saad, Fred
    Chowdhury, Simon
    Oudard, Stephane
    Hadaschik, Boris
    Olmos, David
    Lee, Ji Youl
    Uemura, Hiroji
    Bhaumik, Amitabha
    Londhe, Anil
    Rooney, Brendan
    Brookman-May, Sabine D.
    De Porre, Peter
    Mundle, Suneel D.
    Small, Eric J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 156 - 161
  • [45] Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management
    Alfredo Tartarone
    Rosa Lerose
    Marina Tartarone
    Medical Oncology, 39
  • [46] Physician preferences for non-metastatic castration-resistant prostate cancer treatment
    Srinivas, Sandy
    Mohamed, Ateesha F.
    Appukkuttan, Sreevalsa
    Botteman, Marc
    Ng, Xinyi
    Joshi, Namita
    Horodniceanu, Erica
    Waldeck, A. Reginald
    Simmons, Stacey J.
    BMC UROLOGY, 2020, 20 (01)
  • [47] Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide
    YaoYao Pollock
    Matthew R. Smith
    Fred Saad
    Simon Chowdhury
    Stéphane Oudard
    Boris Hadaschik
    David Olmos
    Ji Youl Lee
    Hiroji Uemura
    Amitabha Bhaumik
    Anil Londhe
    Brendan Rooney
    Sabine D. Brookman-May
    Peter De Porre
    Suneel D. Mundle
    Eric J. Small
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 156 - 161
  • [48] Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Targeted Oncology, 2022, 17 : 381 - 381
  • [49] Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
    Alkhudair, Nora A.
    SAUDI PHARMACEUTICAL JOURNAL, 2019, 27 (03) : 368 - 372
  • [50] The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13